the di¡erence between the detection rates (58% and 62%) observed for the two systems of assays in the smaller series is actually signi¢cant, and likewise for the di¡erence between the rates (85% and 87%) estimated for the real-world situation in which NT measurements would be available.
CIs tabulated here for the di¡erences were calculated on a paired basis, by assuming that the IMMU-LITE 2000 assays detected no DS cases not also detected by the Kryptor assays. This is inherently more favourable to the Kryptor assays than an unpaired analysis, in the sense of yielding narrower CIs and thus a greater tendency to certify the detection rates observed or estimated for the Kryptor assays as signi¢cantly higher. But even on this basis, no signi¢cant di¡erence between the two assay systems can be demonstrated from the results of the clinical study reported in Dr Spencer's article, as the statistics tabulated above attest.
CIs for the detection rates are evidently very broad, largely because of the relatively small number of DS cases involved. CIs for the di¡erences both straddle zero --indeed, zero falls well within the interior of each interval --meaning that the apparent di¡erences in detection rates can not be regarded as signi¢cant at a 95% probability level (or even at considerably lower levels).
In short, the clinical results assembled by Dr Spencer in the present article fail to demonstrate, according to the prevailing standards of evidence-based laboratory medicine, that the DPC assays are signi¢cantly di¡erent from the Brahms assays with respect to the measure of diagnostic accuracy most relevant in this context, namely, ¢rst-trimester detection rates for DS.
Peter Feddema 1 , Leo Vankrieken 2 , Filip de Pillecijn 2 and A Paul Durham 2
Author's reply Feddema et al. 1 from DPC raise some doubts concerning the signi¢cance of ¢ndings reported in my previous paper, 2 which showed that, in comparison with the Kryptor method, the DPC Immulite 2000 method for PAPP-A showed a highly signi¢cant positive bias when examining maternal serum from women with a Down's syndrome pregnancy. This bias of 21.9% (see Figure 10 of the original paper) resulted in a signi¢cantly higher median MoM when measured on the DPC system (0.62) compared with that on Kryptor (0.47).When the individual results were examined in the log-transformed domain, the result was signi¢cantly di¡erent (P ¼ 0.025). Although the con¢dence intervals were not quoted for the median MoM, they were provided, as appropriate, in the log-transformed domain.
The consequence of this 21.9% positive bias on the detection rate in cases with Down's syndrome was the di¡erence between the detection rates (58% and 62%) observed for the two systems of assays in the smaller series is actually signi¢cant, and likewise for the di¡erence between the rates (85% and 87%) estimated for the real-world situation in which NT measurements would be available.
The answer to both questions is evidently 'no'. The observed and estimated di¡erences are small, and readers may well suspect --rightly, in this instance --that a series of only 60 DS cases cannot rule out sampling variation as an explanation for the apparent di¡erences.
The article supplies only point estimates for the detection rates in question, even though it is now generally accepted 2 that con¢dence intervals (CIs) 'should be stated, particularly for nonsigni¢cant results'. No CIs, P-values or other measures are recorded from which the signi¢cance or non-signi¢cance of the stated di¡erences could be read o¡ directly.
Fortunately, there is enough information for a reader to calculate CIs, thereby con¢rming the conclusions left implicit in the article, namely that the detection rates observed and estimated in this study for the IMMULITE 2000 assays were not signi¢cantly lower than those for the Kryptor assays. (In fact, the article does not assert that di¡erences between the IMMULITE 2000 and Kryptor detection rates are statistically sig-ni¢cant.)
The 95% CIs listed below, in parentheses, for the relevant detection rates quoted in Dr Spencer's article, and for their di¡erences, were calculated according to current recommendations:Wilson's method for a proportion and Newcombe's method for a di¡erence in proportions. 3 All values are recorded to two signi¢cant digits.
( CIs tabulated here for the di¡erences were calculated on a paired basis, by assuming that the IMMU-LITE 2000 assays detected no DS cases not also detected by the Kryptor assays. This is inherently more favourable to the Kryptor assays than an unpaired analysis, in the sense of yielding narrower CIs and thus a greater tendency to certify the detection rates observed or estimated for the Kryptor assays as signi¢cantly higher. But even on this basis, no signi¢cant di¡erence between the two assay systems can be demonstrated from the results of the clinical study reported in Dr Spencer's article, as the statistics tabulated above attest.
Peter Feddema 1 , Leo Vankrieken 2 , Filip de Pillecijn 2 and A Paul Durham 2 modelled using standard statistical techniques for population modelling, using 50,000 data-sets for the normal and Down's populations derived from within the described population distributions of the markers, as measured in the two systems. The 95% con¢dence interval in such a modelling exercise with 50,000 Down's syndrome data-sets leads to a detection rate with a con¢dence interval of 70.3% at a 5% falsepositive rate. Thus, when the Kryptor and DPC detection rates as quoted in the paper are compared, the con¢dence interval for Kryptor is 61.7--62.3, while that for DPC is 57.7--58.3. Thus, the Kryptor has a signi-¢cantly higher detection rate than the DPC system.
The workers from DPC have made a number of basic errors and assumptions.
Firstly, they assume that the 60 cases were part of a much larger series of 210 cases published in 1999. 3 My paper quite clearly stated that the cases 'had been collected as part of routine ¢rst trimester screening of women of all ages in our centre over the past 5 years' (i.e. 1999--2004) --they were a collection after the 1999 study was published, and have no relationship to this earlier series.
Secondly, the rather dubious attempt at statistical manipulation of the cases, as if they had been part of the larger series to claim a greater concordance of detection rates between the two systems, is scienti¢cally and statistically £awed. The cases were not part of some larger series and in the paper in question I did not quote detection rates based on the cases themselves, but used the distribution parameters to model expected population detection rates. Thus, in a study of 60 samples, had I quoted the observed detection rate in the series, it would have been appropriate to quote a con¢dence interval, and indeed the con¢dence intervals of the two systems would have overlapped because of the small number of cases. However, this is not what was done --I quoted modelled detection rates based on 50,000 data-sets for the normal population and 50,000 for the Down's population. If Feddema et al. were aware of the literature, they would realize that such population modelling is standard practice and has been shown to be a robust method of getting closer to the 'true' detection rate achieved in routine screening.
While one would expect a company to attempt to put up a spirited defence of its assay, the 'smoke and mirrors' tactics do not hide the fact that, in this series of 60 cases of Down's Syndrome, the DPC assay had a 21.9% positive bias against the Kryptor assay, leading to a higher-than-expected median MoM, which will lead to a reduction in detection rate when used in combination with free b-hCG alone, or additionally with fetal nuchal translucency. The conclusions of my paper --'that better clinical performance is likely to be achieved with alternative platforms to the DPC IMMU-LITE 2000' --are therefore still valid. What DPC as a company should be concentrating on in their R&D facility is why this bias exists, perhaps looking at their choice of monoclonal antibodies in an attempt to improve clinical performance.
HbA 1c or glucose for diabetes diagnosis?
Geberhiwot et al. provided data to support the validity of the approach of combining forms of glycosylated haemoglobin (HbA 1c ) with fasting plasma glucose (FPG) in order to identify patients requiring an oral glucose tolerance test (OGTT). 1 In patients with FPG r6.0 mmol/L, an HbA 1c of 5.6% gave an optimal sensitivity of 72% and speci¢city of 77% to predict a 2 h plasma glucose of Z7.8 mmol/L. In the accompanying editorial, however, Kilpatrick states that it is di⁄cult to see how HbA 1c will ever supplant (or even complement) the measurement of glucose, while the latter test remains the single means by which the diagnosis is decided. 2 Remarkably, neither author refers to the largest national diabetes prevalence study in the developed world to have used OGTT, namely the Australian Diabetes, Obesity and Lifestyle Study 3 (AusDiab) and the Australian screening guidelines that were evaluated against these population data. 4 In brief, a national sample of 11,247 adults aged Z25 years underwent a 75 g OGTT. 3 The prevalence of diabetes was found to be 8.0% in men and 6.8% in women, with an additional 17.4% of men and 15.4% of women having impaired glucose tolerance or impaired fasting glycaemia. 3 The Australian screening guidelines identify risk factors as adults aged Z55 years or those aged Z45 years with
